Richard L Page

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/288489/publications.pdf

Version: 2024-02-01

231 papers

51,814 citations

88 h-index 225 g-index

237 all docs

237 docs citations

times ranked

237

30837 citing authors

#	Article	IF	CITATIONS
1	The Australian ankle syndesmosis injury survey. Injury, 2022, 53, 2304-2310.	1.7	1
2	Effect of glenosphere size on reverse shoulder arthroplasty revision rate: an analysis from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Journal of Shoulder and Elbow Surgery, 2022, 31, e289-e301.	2.6	10
3	Total shoulder replacement stems in osteoarthritis—short, long, or reverse? An analysis of the impact of crosslinked polyethylene. Journal of Shoulder and Elbow Surgery, 2022, 31, 2249-2255.	2.6	4
4	Ultraprocessed food and chronic noncommunicable diseases: A systematic review and metaâ€analysis of 43 observational studies. Obesity Reviews, 2021, 22, e13146.	6.5	298
5	Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines–Atrial Fibrillation Registry. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008961.	4.8	11
6	The Closing Argument for Surgical Left Atrial Appendage Occlusion. New England Journal of Medicine, 2021, 384, 2154-2155.	27.0	6
7	Predicting fracture outcomes from clinical registry data using artificial intelligence supplemented models for evidence-informed treatment (PRAISE) study protocol. PLoS ONE, 2021, 16, e0257361.	2.5	4
8	Reverse total shoulder arthroplasty compared to stemmed hemiarthroplasty for proximal humeral fractures: a registry analysis of 5946 patients. Journal of Shoulder and Elbow Surgery, 2020, 29, 2538-2547.	2.6	22
9	Genicular Artery Embolization to Improve Pain and Function in Early-Stage Knee Osteoarthritis—24-Month Pilot Study Results. Journal of Vascular and Interventional Radiology, 2020, 31, 1453-1458.	0.5	46
10	The road to recovery for vulnerable road users hospitalised for orthopaedic injury following an on-road crash. Accident Analysis and Prevention, 2019, 132, 105279.	5.7	11
11	Core Set of Radiographic Parameters for Shoulder Arthroplasty Monitoring. JBJS Open Access, 2019, 4, e0025.	1.5	17
12	Monocortical fixation of the coracoid in the Latarjet procedure is significantly weaker than bicortical fixation. Knee Surgery, Sports Traumatology, Arthroscopy, 2019, 27, 239-244.	4.2	14
13	Psychogenic pseudosyncope: Not always a diagnosis of exclusion. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 480-486.	1.2	15
14	Pâ€Wave Amplitude and PR Changes in Patients With Inappropriate Sinus Tachycardia: Findings Supportive of a Central Mechanism. Journal of the American Heart Association, 2018, 7, .	3.7	14
15	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary. Heart Rhythm, 2018, 15, e190-e252.	0.7	448
16	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm, 2018, 15, e73-e189.	0.7	262
17	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Journal of the American College of Cardiology, 2018, 72, 1677-1749.	2.8	382
18	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Circulation, 2018, 138, e210-e271.	1.6	250

#	Article	IF	Citations
19	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 2018, 138, e272-e391.	1.6	468
20	Operative shoulder instability injury management in Australian Football League players: A case series. Journal of Science and Medicine in Sport, 2018, 21, 760-764.	1.3	10
21	Another Shock for Sudden Death Prevention after Myocardial Infarction. New England Journal of Medicine, 2018, 379, 1274-1275.	27.0	11
22	Effects of Prolonged Spaceflight on Atrial Size, Atrial Electrophysiology, and Risk of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005959.	4.8	26
23	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	2.8	991
24	Twelve-month work–related outcomes following hip fracture in patients under 65 years of age. Injury, 2017, 48, 701-707.	1.7	18
25	Clinical Characteristics and Outcome of Patients with Situational Syncope Compared to Patients with Vasovagal Syncope. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 591-595.	1.2	10
26	Do non-steroidal anti-inflammatory drugs impair fracture healing? A survey of Australian orthopaedic surgeons. Journal of Pharmacy Practice and Research, 2017, 47, 393-395.	0.8	0
27	The subcutaneous defibrillator: Modest step or quantum leap?. Heart Rhythm, 2017, 14, 1464-1465.	0.7	1
28	The Right Place at the Right Time. Circulation, 2017, 135, 1120-1122.	1.6	9
29	Ongoing Management of Patients With Supraventricular Tachycardia. JAMA Cardiology, 2017, 2, 332.	6.1	6
30	Quality of Evidence Underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the Management of Atrial Fibrillation. JAMA Cardiology, 2017, 2, 319.	6.1	17
31	Predictors of recovery in cyclists hospitalised for orthopaedic trauma following an on-road crash. Accident Analysis and Prevention, 2017, 106, 341-347.	5.7	17
32	Out-of-Hospital Cardiac Arrest â€" Are Drugs Ever the Answer?. New England Journal of Medicine, 2016, 374, 1781-1782.	27.0	10
33	Longâ€Term Outcome of Patients with Bifascicular Block and Unexplained Syncope Following Cardiac Pacing. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1126-1131.	1.2	23
34	The US Food and Drug Administration Premarket Approval Process and the 515 Program Initiative. JAMA Cardiology, 2016, 1, 119.	6.1	0
35	The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial. Trials, 2016, 17, 395.	1.6	16
36	Restoring Sinus Rhythm Improves Baroreflex Function in Patients With Persistent Atrial Fibrillation. Journal of the American Heart Association, 2016, 5, .	3.7	13

#	Article	IF	Citations
37	Acute Treatment of Patients With Supraventricular Tachycardia. JAMA Cardiology, 2016, 1, 483.	6.1	2
38	The pathophysiologic mechanisms associated with hypotensive susceptibility. Clinical Autonomic Research, 2016, 26, 261-268.	2.5	5
39	The Role of the Baroreflex in TiltÂTableÂTesting. JACC: Clinical Electrophysiology, 2016, 2, 812-817.	3.2	10
40	Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death. Circulation, 2016, 133, 1715-1727.	1.6	108
41	Risk stratification for arrhythmic events in patients with asymptomatic pre-excitation: A systematic review for the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. Heart Rhythm, 2016, 13, e222-e237.	0.7	16
42	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. Heart Rhythm, 2016, 13, e136-e221.	0.7	84
43	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Journal of the American College of Cardiology, 2016, 67, e27-e115.	2.8	325
44	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation, 2016, 133, e506-74.	1.6	320
45	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary. Circulation, 2016, 133, e471-505.	1.6	96
46	Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Journal of the American College of Cardiology, 2016, 67, 1624-1638.	2.8	43
47	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: Executive summary. Heart Rhythm, 2016, 13, e92-e135.	0.7	23
48	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary. Journal of the American College of Cardiology, 2016, 67, 1575-1623.	2.8	86
49	Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation, 2016, 133, e575-86.	1.6	42
50	Mechanisms of sinus node cycle length changes during ventricular fibrillation. Clinical Autonomic Research, 2015, 25, 399-406.	2.5	0
51	"Vasovagal―Response during Ventricular Fibrillation: Incidence and Implications. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 376-382.	1.2	1
52	Antiarrhythmic drugs in pregnancy. Expert Review of Cardiovascular Therapy, 2015, 13, 1433-1444.	1.5	11
53	Cardiac Arrest in Pregnancy. Circulation, 2015, 132, 1747-1773.	1.6	290
54	Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace, 2014, 16, 174-181.	1.7	29

#	Article	IF	CITATIONS
55	Management of arrhythmia syndromes during pregnancy. Current Opinion in Cardiology, 2014, 29, 36-44.	1.8	40
56	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Circulation, 2014, 130, 94-125.	1.6	102
57	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Heart Rhythm, 2014, 11, 1270-1303.	0.7	16
58	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Journal of the American College of Cardiology, 2014, 64, 1143-1177.	2.8	118
59	Cardiac Arrest at Exercise Facilities. Journal of the American College of Cardiology, 2013, 62, 2102-2109.	2.8	34
60	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Journal of the American College of Cardiology, 2013, 61, e6-e75.	2.8	736
61	Fish Oil and Post-Operative Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2194-2196.	2.8	52
62	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2013, 127, e283-352.	1.6	803
63	Fish Oil and Postoperative Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2012, 308, 2001.	7.4	201
64	2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2012, 126, 1784-1800.	1.6	321
65	Latency of ECG Displays of Hospital Telemetry Systems. Circulation, 2012, 126, 1665-1669.	1.6	7
66	Advances in Resuscitation. Circulation, 2012, 126, 991-1002.	1.6	9
67	2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, e127-e145.	0.8	44
68	Ventricular Arrhythmias in the Elderly. Clinics in Geriatric Medicine, 2012, 28, 665-677.	2.6	6
69	Wenckebach Periodicity at Rest That Normalizes With Tachycardia in a Family With a NKX2.5 Mutation. American Journal of Cardiology, 2012, 110, 1646-1650.	1.6	14
70	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) Tj ET	Qq0,0 0 rg	ßBT /Oyerlock :
71	Public Access Defibrillation. Heart Failure Clinics, 2011, 7, 269-276.	2.1	3

2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq0 0.0 rgBT /Qyerlock 10

#	Article	IF	CITATIONS
73	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) Tj ETQq	1,1,0.784 2.8	314 rgBT /O
74	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq0) 8.9 rgBT /	Overlock 10
75	Guidance for the Heart Rhythm Society Pertaining to Interactions with Industry. Heart Rhythm, 2011, 8, e19-e25.	0.7	4
76	The ω-3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trial—rationale and design. American Heart Journal, 2011, 162, 56-63.e3.	2.7	31
77	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 1303-1338.	0.8	73
78	2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, e153-e203.	0.8	260
79	Rhythm- and Rate-Controlling Effects of Dronedarone in Patients With Atrial Fibrillation (from the) Tj ETQq1 1 0.78	84314 rgB 1.6	T_ Overlock 57
80	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) Tj ETQq	0,0 0 rgBT	Qyerlock 1
81	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq1	1.0.7843	14 ggBT / <mark>O</mark> v
82	2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2011, 123, e269-367.	1.6	747
83	Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace, 2011, 13, 1118-1126.	1.7	33
84	Arrhythmias in Pregnancy and Postpartum. , 2011, , 339-354.		0
85	The AED in resuscitation: it's not just about the shock. Transactions of the American Clinical and Climatological Association, 2011, 122, 347-55.	0.5	4
86	Diabetes Mellitus, Glycemic Control, and Risk of Atrial Fibrillation. Journal of General Internal Medicine, 2010, 25, 853-858.	2.6	238
87	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease: Executive Summary. Catheterization and Cardiovascular Interventions, 2010, 76, E43-86.	1.7	260
88	Community Approaches to Improve Resuscitation After Out-of-Hospital Sudden Cardiac Arrest. Circulation, 2010, 121, 1134-1140.	1.6	83
89	Dronedarone in patients with congestive heart failure: insights from ATHENA. European Heart Journal, 2010, 31, 1717-1721.	2.2	61
90	The President's page: The Heart Rhythm Society launches new strategic plan. Heart Rhythm, 2010, 7, 722-723.	0.7	1

#	Article	IF	CITATIONS
91	Acute Antiarrhythmic Therapy of Ventricular Tachycardia and Ventricular Fibrillation. Cardiac Electrophysiology Clinics, 2010, 2, 429-441.	1.7	O
92	To the Editor: Responseâ€"Irreplaceable antiarrhythmic medications are disappearing: the case of quinidine. Heart Rhythm, 2010, 7, 863-864.	0.7	1
93	2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of the American College of Cardiology, 2010, 56, e50-e103.	2.8	1,150
94	Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: A Cardiac Safety Research Consortium "Incubator― Think Tank. American Heart Journal, 2010, 159, 17-24.e1.	2.7	20
95	High-frequency ventricular ectopy can increase sympathetic neural activity in humans. Heart Rhythm, 2010, 7, 497-503.	0.7	35
96	Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. New England Journal of Medicine, 2009, 360, 668-678.	27.0	1,029
97	Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter. Circulation, 2009, 120, 1174-1180.	1.6	228
98	Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace, 2009, 11 , 860-885.	1.7	104
99	Pharmacological therapy for atrial fibrillation: current options and new agents. Expert Opinion on Investigational Drugs, 2009, 18, 417-431.	4.1	5
	117 Code Battorial Orago, 2007, 10, 117 131.		
100	Dronedarone. Nature Reviews Drug Discovery, 2009, 8, 769-770.	46.4	10
100		1.7	10
	Dronedarone. Nature Reviews Drug Discovery, 2009, 8, 769-770.		
101	Dronedarone. Nature Reviews Drug Discovery, 2009, 8, 769-770. Public Access Defibrillation. Cardiac Electrophysiology Clinics, 2009, 1, 33-40. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference †research perspectives in AF'. European Heart Journal,	1.7	0
101	Dronedarone. Nature Reviews Drug Discovery, 2009, 8, 769-770. Public Access Defibrillation. Cardiac Electrophysiology Clinics, 2009, 1, 33-40. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference †research perspectives in AF'. European Heart Journal, 2009, 30, 2969-2980. Frequency and Outcome of Arrhythmias Complicating Admission During Pregnancy: Experience From a	2.2	0 173
101 102 103	Dronedarone. Nature Reviews Drug Discovery, 2009, 8, 769-770. Public Access Defibrillation. Cardiac Electrophysiology Clinics, 2009, 1, 33-40. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference †research perspectives in AF'. European Heart Journal, 2009, 30, 2969-2980. Frequency and Outcome of Arrhythmias Complicating Admission During Pregnancy: Experience From a Highâ€volume and Ethnicallyâ€diverse Obstetric Service. Clinical Cardiology, 2008, 31, 538-541. Azimilide for the Treatment of Atrial Fibrillation, Atrial Flutter, and Paroxysmal Supraventricular Tachycardia: Results of a Randomized Trial and Insights on the Concordance of Symptoms and	1.7 2.2 1.8	0 173 131
101 102 103	Dronedarone. Nature Reviews Drug Discovery, 2009, 8, 769-770. Public Access Defibrillation. Cardiac Electrophysiology Clinics, 2009, 1, 33-40. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference †research perspectives in AFâ€. European Heart Journal, 2009, 30, 2969-2980. Frequency and Outcome of Arrhythmias Complicating Admission During Pregnancy: Experience From a Highâ€volume and Ethnicallyâ€diverse Obstetric Service. Clinical Cardiology, 2008, 31, 538-541. Azimilide for the Treatment of Atrial Fibrillation, Atrial Flutter, and Paroxysmal Supraventricular Tachycardia: Results of a Randomized Trial and Insights on the Concordance of Symptoms and Recurrent Arrhythmias. Journal of Cardiovascular Electrophysiology, 2008, 19, 172-177. Approach to the Diagnosis and Initial Management of the Stable Adult Patient With a Wide Complex	1.7 2.2 1.8	0 173 131 17
101 102 103 104	Dronedarone. Nature Reviews Drug Discovery, 2009, 8, 769-770. Public Access Defibrillation. Cardiac Electrophysiology Clinics, 2009, 1, 33-40. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference †research perspectives in AF†. European Heart Journal, 2009, 30, 2969-2980. Frequency and Outcome of Arrhythmias Complicating Admission During Pregnancy: Experience From a High†volume and Ethnically†diverse Obstetric Service. Clinical Cardiology, 2008, 31, 538-541. Azimilide for the Treatment of Atrial Fibrillation, Atrial Flutter, and Paroxysmal Supraventricular Tachycardia: Results of a Randomized Trial and Insights on the Concordance of Symptoms and Recurrent Arrhythmias. Journal of Cardiovascular Electrophysiology, 2008, 19, 172-177. Approach to the Diagnosis and Initial Management of the Stable Adult Patient With a Wide Complex Tachycardia. American Journal of Cardiology, 2008, 101, 1456-1466. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for	1.7 2.2 1.8 1.7	0 173 131 17

#	Article	IF	CITATIONS
109	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary. Heart Rhythm, 2008, 5, 934-955.	0.7	367
110	American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Heart Rhythm, 2008, 5, e1-e21.	0.7	61
111	American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Circulation, 2008, 118, 1497-1518.	1.6	903
112	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary. Circulation, 2008, 117, 2820-2840.	1.6	175
113	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2008, 117, e350-408.	1.6	1,358
114	Hands-Only (Compression-Only) Cardiopulmonary Resuscitation: A Call to Action for Bystander Response to Adults Who Experience Out-of-Hospital Sudden Cardiac Arrest. Circulation, 2008, 117, 2162-2167.	1.6	335
115	ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary. Anesthesia and Analgesia, 2008, 106, 685-712.	2.2	214
116	American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and	1.6	90
117	Prevention. Circulation, 2008, 118, 1497-1518. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Circulation, 2007, 116, e148-304.	1.6	1,247
118	Short QT. Circulation, 2007, 116, 686-688.	1.6	10
118	Short QT. Circulation, 2007, 116, 686-688. Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. JAMA - Journal of the American Medical Association, 2007, 297, 2502.	1.6 7.4	10 497
	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. JAMA -		
119	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. JAMA - Journal of the American Medical Association, 2007, 297, 2502. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac	7.4	497
119	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. JAMA - Journal of the American Medical Association, 2007, 297, 2502. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary. Circulation, 2007, 116, 1971-1996. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac	7.4 1.6	497 612
119 120 121	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. JAMA-Journal of the American Medical Association, 2007, 297, 2502. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary. Circulation, 2007, 116, 1971-1996. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. Circulation, 2007, 116, e418-99. Pharmacological therapy of atrial fibrillation. Expert Opinion on Investigational Drugs, 2007, 16,	7.4 1.6	497 612 644
119 120 121 122	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. JAMA - Journal of the American Medical Association, 2007, 297, 2502. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary. Circulation, 2007, 116, 1971-1996. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. Circulation, 2007, 116, e418-99. Pharmacological therapy of atrial fibrillation. Expert Opinion on Investigational Drugs, 2007, 16, 169-179.	7.4 1.6 1.6 4.1	49761264413
119 120 121 122	Cardiac Resynchronization Therapy for Patients With Left Ventricular Systolic Dysfunction. JAMA - Journal of the American Medical Association, 2007, 297, 2502. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary. Circulation, 2007, 116, 1971-1996. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. Circulation, 2007, 116, e418-99. Pharmacological therapy of atrial fibrillation. Expert Opinion on Investigational Drugs, 2007, 16, 169-179. Medical management of atrial fibrillation: Future directions. Heart Rhythm, 2007, 4, S91-S94. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation	7.4 1.6 1.6 4.1	4976126441317

#	Article	IF	CITATIONS
127	The Automated External Defibrillator. Journal of Cardiovascular Electrophysiology, 2007, 18, 896-899.	1.7	23
128	Rationale and Design of ATHENA: A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in PatiENts with Atrial Fibrillation/Atrial Flutter. Journal of Cardiovascular Electrophysiology, 2007, 19, 071121154351003-???.	1.7	51
129	ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2006, 48, e247,e346, 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower) Tj ETQq0 0 0	2.8 rgBT /Ove	1,280 erlock 10 Tf 5
130	the American Association for Vascular Surgery/Society for Vascular Surgery,âŽâŽAAVS/SVS when Guideline initiated, now merged into SVSSociety for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task	2.8	1,012
131	Force on Practice Guidelines. Journal of the American College of Cardiology, 2006, 47, 1239-1312. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2006, 47, e1-e121 ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower) Tj ETQq0 0 0	2.8 rgBT /Ove	435 rlock 10 Tf 5
132	Association for Vascular Surgery/Society for Vascular Surgery,âŽSociety for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional		

#	Article	IF	Citations
145	ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Interventionâ€"Summary Article. Circulation, 2006, 113, 156-175.	1.6	987
146	Antiarrhythmic Drugs for All Patients With an ICD?. JAMA - Journal of the American Medical Association, 2006, 295, 211.	7.4	6
147	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillationâ€"Executive Summary. Circulation, 2006, 114, 700-752. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the	1.6	294
148	prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias) Tj ETQq0	о d 7 gвт /(Overlock 10 ⁻
149	Rhythm Association and the Heart R. Europace, 2006, 8, 746-837. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary. European Heart Journal, 2006, 27, 1979-2030.	2.2	612
150	ACC/AHA/SCAI Practice Guidelines, February 21, 2006. Circulation, 2006, 113, e166-286.	1.6	525
151	ACC/AHA 2006 Guideline Update on Perioperative Cardiovascular Evaluation for Noncardiac Surgery: Focused Update on Perioperative Beta-Blocker Therapy. Circulation, 2006, 113, 2662-2674.	1.6	165
152	ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). Circulation, 2006, 113, e463-654.	1.6	2,927
153	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Circulation, 2006, 114, e257-354.	1.6	2,120
154	Drug therapy for atrial fibrillation: where do we go from here?. Nature Reviews Drug Discovery, 2005, 4, 899-910.	46.4	59
155	Relation of Echocardiographic Wall Motion Score Index and Response to Dobutamine Stress to Defibrillation Threshold at the Time of Implantation of a Cardiac Defibrillator. American Journal of Cardiology, 2005, 95, 1099-1101.	1.6	2
156	Asymptomatic Atrial Fibrillation. Progress in Cardiovascular Diseases, 2005, 48, 79-87.	3.1	102
157	New treatment options for stroke prevention in atrial fibrillation. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 341-349.	0.9	0
158	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation, 2005, 112, e154-235.	1.6	2,179
159	Electrocardiographic Predictors of Arrhythmic Death and Total Mortality in the Multicenter Unsustained Tachycardia Trial. Circulation, 2004, 110, 766-769.	1.6	162
160	Early Recurrence of Atrial Fibrillation:. Journal of Cardiovascular Electrophysiology, 2004, 15, 898-900.	1.7	3
161	Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. Heart Rhythm, 2004, 1 , 435-440.	0.7	21
162	Newly Diagnosed Atrial Fibrillation. New England Journal of Medicine, 2004, 351, 2408-2416.	27.0	115

#	Article	IF	Citations
163	Biphasic Versus Monophasic Shock Waveform for Conversion of Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 290-291.	1.0	6
164	Sympathoexcitation is attenuated during low level lower body negative pressure in subjects who develop pre-syncope. Clinical Autonomic Research, 2003, 13, 208-213.	2.5	12
165	Poor baroreflex gain is a marker of heightened sympathetic activity post-tachycardia termination in humans. Clinical Autonomic Research, 2003, 13, 443-446.	2.5	4
166	Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. American Journal of Cardiology, 2003, 92, 941-946.	1.6	102
167	Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. American Heart Journal, 2003, 146, 489-493.	2.7	22
168	Effect of Atrial Fibrillation and an Irregular Ventricular Response on Sympathetic Nerve Activity in Human Subjects. Circulation, 2003, 107, 2011-2015.	1.6	135
169	The Automated External Defibrillator: Critical Link in the Chain of Survival. Annual Review of Medicine, 2003, 54, 235-243.	12.2	10
170	Asymptomatic or "Silent―Atrial Fibrillation. Circulation, 2003, 107, 1141-1145.	1.6	171
171	Racial Differences in Outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). Circulation, 2003, 108, 67-72.	1.6	32
172	Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators Trial. Circulation, 2002, 105, 589-594.	1.6	588
173	Automated External Defibrillator Use by Police Responders. Circulation, 2002, 106, 1030-1033.	1.6	5
174	Serotonin Reuptake Inhibitor (Paxil) Does Not Prevent the Vasovagal Reaction Associated With Carotid Sinus Massage and/or Lower Body Negative Pressure in Healthy Volunteers. Circulation, 2002, 106, 1500-1504.	1.6	50
175	Effects of Azimilide on Heart Rate and ECG Conduction Intervals during Sinus Rhythm in Patients with a History of Atrial Fibrillation. Journal of Clinical Pharmacology, 2002, 42, 388-394.	2.0	7
176	Biphasic versus monophasic shock waveform for conversion of atrial fibrillation. Journal of the American College of Cardiology, 2002, 39, 1956-1963.	2.8	204
177	Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response. American Heart Journal, 2002, 143, 643-649.	2.7	36
178	Effects of resynchronization therapy on sympathetic activity in patients with depressed ejection fraction and intraventricular conduction delay due to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 2002, 89, 1047-1051.	1.6	54
179	Arrhythmias occurring during pregnancy. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 136-139.	1.0	16
180	Automated External Defibrillators: Technical Considerations and Clinical Promise. Annals of Internal Medicine, 2001, 135, 990.	3.9	37

#	Article	IF	Citations
181	Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. American Heart Journal, 2001, 142, 498-501.	2.7	124
182	Asymptomatic Atrial Fibrillation. Chest, 2001, 119, 628-631.	0.8	2
183	Antiarrhythmic drugs in pregnancy. Current Opinion in Cardiology, 2001, 16, 40-45.	1.8	59
184	The Hot Can: ICD Failure Presenting as Severe Shoulder Pain. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 396-397.	1.2	4
185	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 31-34.	1.0	0
186	Biventricular pacing decreases the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. American Journal of Cardiology, 2001, 87, 1208-1210.	1.6	84
187	Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. American Journal of Cardiology, 2001, 88, 446-448.	1.6	16
188	Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. American Journal of Cardiology, 2001, 88, 974-979.	1.6	83
189	Effect of P-Wave Timing During Supraventricular Tachycardia on the Hemodynamic and Sympathetic Neural Response. Circulation, 2001, 103, 96-101.	1.6	27
190	Selective parasympathetic denervation following posteroseptal ablation for either atrioventricular nodal reentrant tachycardia or accessory pathways. American Journal of Cardiology, 2000, 85, 875-878.	1.6	11
191	Effects of antiarrhythmic medication on implantable cardioverter-defibrillator function. American Journal of Cardiology, 2000, 85, 1481-1485.	1.6	32
192	Initial energy for elective external cardioversion of persistent atrial fibrillation. American Journal of Cardiology, 2000, 86, 348-350.	1.6	84
193	Propafenone. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 288-291.	1.0	0
194	Use of Automated External Defibrillators by a U.S. Airline. New England Journal of Medicine, 2000, 343, 1210-1216.	27.0	620
195	Biventricular Pacing Decreases Sympathetic Activity Compared With Right Ventricular Pacing in Patients With Depressed Ejection Fraction. Circulation, 2000, 102, 1027-1032.	1.6	142
196	Azimilide dihydrochloride: a new class III anti-arrhythmic agent. Expert Opinion on Investigational Drugs, 2000, 9, 2705-2715.	4.1	10
197	Increased sympathetic activity after atrioventricular junction ablation in patients with chronic atrial fibrillation. Journal of the American College of Cardiology, 2000, 36, 151-158.	2.8	27
198	Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Journal of the American College of Cardiology, 2000, 36, 794-802.	2.8	106

#	Article	IF	Citations
199	Reflex Control of Sympathetic Activity During Simulated Ventricular Tachycardia in Humans. Circulation, 1999, 100, 628-634.	1.6	33
200	Baroreflex Gain Predicts Blood Pressure Recovery During Simulated Ventricular Tachycardia in Humans. Circulation, 1999, 100, 381-386.	1.6	44
201	The Effect of Biphasic Defibrillation on the Immediate Pacing Threshold of a Dedicated Bipolar, Steroid-Eluting Lead. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 1229-1233.	1.2	8
202	Arrhythmias in Pregnancy. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 227-229.	1.0	1
203	Effects of repeated electrical defibrillations on cardiac troponin I levels. American Journal of Cardiology, 1999, 83, 270-272.	1.6	97
204	Interaction of a commercial heart rate monitor with implanted pacemakers. American Journal of Cardiology, 1999, 83, 790-792.	1.6	5
205	Effect of radiofrequency ablation on atrial mechanical function in patients with atrial flutter. American Journal of Cardiology, 1999, 84, 420-425.	1.6	27
206	Treatment of Cardiac Arrhythmias During Pregnancy. Drug Safety, 1999, 20, 85-94.	3.2	119
207	Management of ventricular arrhythmias. Journal of the American College of Cardiology, 1999, 34, 621-630.	2.8	13
208	Automatic External Cardioverter-Defibrillator Therapy. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 260-262.	1.0	1
209	Propafenone. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 204-206.	1.0	5
210	Intracardiac shunts resulting from transseptal catheterization for ablation of accessory pathways in otherwise normal hearts. American Journal of Cardiology, 1998, 82, 391-392.	1.6	3
211	Defibrillation Aboard a Commercial Aircraft. Circulation, 1998, 97, 1429-1430.	1.6	52
212	Initial experience with a high-impedance tined endocardial pacemaker lead: Evidence for increased lead failure. American Heart Journal, 1997, 134, 161-164.	2.7	14
213	Does Digoxin Provide Additional Hemodynamic and Autonomic Benefit at Higher Doses in Patients With Mild to Moderate Heart Failure and Normal Sinus Rhythm?. Journal of the American College of Cardiology, 1997, 29, 1206-1213.	2.8	128
214	Determinants of Nonthoracotomy Biphasic Defihrillation. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 60-64.	1.2	14
215	Diagnostic Approach to Narrow Complex Tachycardia with VA Block. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2984-2988.	1.2	27
216	Correlation Between Time-Domain Measures of Heart Rate Variability and Scatterplots in Patients With Healed Myocardial Infarcts and the Influence of Metoprolol. American Journal of Cardiology, 1997, 79, 412-414.	1.6	18

#	Article	IF	Citations
217	Arrhythmias During Pregnancy. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 278-282.	1.0	3
218	Influence of metoprolol on heart rate variability in survivors of remote myocardial infarction. American Journal of Cardiology, 1996, 77, 557-560.	1.6	28
219	Effect of biphasic endocardial countershock on pacing threskolds in humans. American Journal of Cardiology, 1996, 77, 527-528.	1.6	7
220	Effect of continuous vagal enhancement on concealed conduction and refractoriness within the atrioventricular node. American Journal of Cardiology, 1996, 77, 260-265.	1.6	42
221	Selective radiofrequency ablation of the "slow―atrioventricular nodal pathway for control of the ventricular response to atrial fibrillation. American Journal of Cardiology, 1996, 77, 1358-1361.	1.6	16
222	Use of transesophageal atrial pacing with adenosine infusion to evaluate ventricular preexcitation. American Journal of Cardiology, 1995, 75, 548-550.	1.6	2
223	Heart Rate During Spontaneous and Induced Paroxysmal Supraventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 2155-2157.	1.2	4
224	Diagnosis of ICD Lead Failure Using Continuous Event Marker Recording. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 1331-1334.	1.2	8
225	Treatment of arrhythmias during pregnancy. American Heart Journal, 1995, 130, 871-876.	2.7	178
226	Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. Journal of the American College of Cardiology, 1995, 25, 984-988.	2.8	62
227	Evaluation of Outpatients Experiencing Implantable Cardioverter Defibrillator Shocks Associated with Minimal Symptoms. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 938-943.	1.2	7
228	Radiofrequency Catheter Ablation of Idiopathic Recurrent Ventricular Tachycardia with Right Bundle Branch Block, Left Axis Morphology. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 327-336.	1.2	62
229	Utility of transtelephonic ECG monitoring in evaluating discharges from a third-generation implantable cardioverter defibrillator. Journal of Electrocardiology, 1993, 26, 235-238.	0.9	4
230	Bidisomide (SC-40230), a new antiarrhythmic agent: Initial study of tolerability and pharmacokinetics. Clinical Pharmacology and Therapeutics, 1992, 51, 371-378.	4.7	6
231	Treatment of supraventricular tachycardias with transcatheter delivery of radiofrequency current. American Journal of Medicine, 1992, 93, 549-557.	1.5	2